Current partner codePEPTIDESDE
NCT06313528·Phase 1·INTERVENTIONAL

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Status

Completed

Phase

Phase 1

Enrollment

85

Locations

3

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Interventions

Treatment arms and agents.

DRUG

LY3437943

Administered SC

OTHER

Placebo

Administered SC

Timeline

From registration to results.

  1. First posted

    Mar 15, 2024

  2. Study start

    Mar 20, 2024

  3. Primary completion

    Aug 26, 2025

  4. Study completion

    Aug 26, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Sep 23, 2025

Outcomes

What the study measures.

Primary outcomes

Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)

Time frame · Baseline up to Week 17 (inclusive)

Secondary outcomes

Change from Baseline in Sleep Metabolic Rate (SMR)

Time frame · Baseline up to Week 16 (inclusive)

In participants who achieve target weight loss

Change from Baseline in SMR

Time frame · Baseline up to Week 16 (inclusive)

Change from Baseline in 24-hour Energy Expenditure (EE)

Time frame · Baseline up to Week 16 (inclusive)

In participants who achieve target weight loss

Change from Baseline in 24-hour EE

Time frame · Baseline up to Week 16 (inclusive)

Change from Baseline in Total Calorie Intake at Lunch

Time frame · Baseline up to Week 17 (inclusive)

Change from Baseline in Total Calorie Intake at Dinner

Time frame · Baseline up to Week 17 (inclusive)

Change from Baseline in Fasting Appetite Visual Analog Score (VAS)

Time frame · Baseline up to Week 16 (inclusive)

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
60 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * BMI greater than 30 kg/m2 * History of at least 1 self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study * Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty * Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity * Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state * Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2 * Acute or chronic hepatitis * Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure * History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior * History of chronic or acute pancreatitis * Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia * Clinically significant multiple or severe drug allergies * Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain * History of substance use disorder

Study locations

3 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

AdventHealth Orlando

Orlando, Florida, United States

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Columbia University Irving Medical Center

New York, New York, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Retatrutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.